{"disease":{"id":"primary-membranous-nephropathy","name":"primary membranous nephropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT06924476","title":"Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":282,"lead_sponsor_name":"Yipeng Liu","has_results":false},{"nct_id":"NCT06470191","title":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":216,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT06893328","title":"A Real World Study About PMN","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wei Chen","has_results":false},{"nct_id":"NCT06962800","title":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07204275","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT06614985","title":"The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":172,"lead_sponsor_name":"Renmin Hospital of Wuhan University","has_results":false},{"nct_id":"NCT07029139","title":"A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05696613","title":"A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"Cerium Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06781944","title":"OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04629248","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":142,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06642909","title":"A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":135,"lead_sponsor_name":"BioRay Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06573411","title":"Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":116,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05398653","title":"A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Beijing Mabworks Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT05514015","title":"Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05136456","title":"Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":61,"lead_sponsor_name":"Reistone Biopharma Company Limited","has_results":false},{"nct_id":"NCT05668403","title":"A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT07157787","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05800873","title":"Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Everest Medicines (China) Co.,Ltd.","has_results":false},{"nct_id":"NCT06120673","title":"REmission in Membranous Nephropathy International Trial (REMIT)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Queensland","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}